stockrow
Saturday 7 November 2026
Export ARTL’s income statement to Excel — free account
Artelo Biosciences, Inc.
ARTL Healthcare Biotechnology
- EPS
- +94.7%
- Free cash flow
- −879.2%
Quarter to June 2026, against a year earlier
1.91
0.21
−9.91%
Follow ARTL
Alert me
Artelo Biosciences, Inc. (ARTL) P/E ratio
Artelo Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ARTL Artelo Biosciences, Inc. | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)